Evicenter
P&T meetings

Atebrioz (zilurgisertib)

Fibrodysplasia ossificans progressiva

Also known as INCB000928
Regulatory submission
NDA submitted by May 2026
Last updated
96 sources

Economic information and modeling reportBudget impact model

Model outcomes

1 evidence topic · 1 source

Budget impact model of zilurgisertib: model outcomes

No evidence found.

Palovarotene cost-utility model submitted to CADTH: outcomes estimated

“The analysis was conducted from the perspective of the Canadian public health care payer. Costs and clinical outcomes (life-years [LYs] and quality-adjusted life-years [QALYs]) were estimated over a lifetime time horizon of 80 years (1-year cycle length), discounted at an annual rate of 1.5% per annum.” (opens the source at this quote in a new tab)